-
(2017)
Molecular alterations in
triple-negative breast cancer-the road to new treatment
strategies
, 389
-
Laurence
Booth,
Jane
Roberts,
M.
Tavallai,
T.
Webb,
Daniel
Leon,
Jesse
Chen,
W.
Mcguire,
A.
Poklepovic,
P.
Dent
(2016)
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
Oncotarget, 7
-
(2011)
SRC-family kinases mediate epidermal growth
factor receptor signaling from lipid rafts in breast cancer
cells
, 12
-
(2011)
SRC: a potential target for
the treatment of triple-negative breast cancer
, 22
-
(2004)
Immunohistochemical and
clinical characterization of the basal-like subtype of invasive breast
carcinoma
, 10
-
(2012)
Understanding the biology of
triple-negative breast cancer
, 23
-
R.
Sharpe,
A.
Pearson,
M.
Herrera-Abreu,
Damian
Johnson,
A.
Mackay,
J.
Welti,
R.
Natrajan,
Andrew
Reynolds,
J.
Reis-Filho,
A.
Ashworth,
N.
Turner
(2011)
FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
Clinical Cancer Research, 17
-
(2002)
The BCL2 family: regulators of the cellular
life-or-death switch
, 2
-
Arman
Jahangiri,
W.
Weiss
(2013)
It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19 21
-
(2009)
Invasive ductal carcinoma of
the breast with the “triple-negative” phenotype: prognostic implications of
EGFR immunoreactivity
, 116
-
G.
Minckwitz,
W.
Jonat,
P.
Fasching,
A.
Bois,
U.
Kleeberg,
H.
Lück,
E.
Kettner,
J.
Hilfrich,
W.
Eiermann,
J.
Torode,
A.
Schneeweiss
(2004)
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
Breast Cancer Research and Treatment, 89
-
Patricia
Keller,
Amy
Lin,
Lisa
Arendt,
I.
Klebba,
A.
Jones,
J.
Rudnick,
Theresa
DiMeo,
Hannah
Gilmore,
D.
Jefferson,
R.
Graham,
S.
Naber,
S.
Schnitt,
C.
Kuperwasser
(2010)
Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines
Breast Cancer Research : BCR, 12
-
(2010)
Mapping the cellular and
molecular heterogeneity of normal and malignant breast tissues and cultured
cell lines
, 12
-
Alexandra
Canonici,
M.
Gijsen,
M.
Mullooly,
R.
Bennett,
Noujoude
Bouguern,
Kasper
Pedersen,
Neil
O’Brien,
I.
Roxanis,
Ji-Liang
Li,
Esther
Bridge,
R.
Finn,
D.
Slamon,
P.
McGowan,
M.
Duffy,
N.
O'Donovan,
J.
Crown,
A.
Kong
(2013)
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Oncotarget, 4
-
(2013)
Neratinib overcomes
trastuzumab resistance in HER2 amplified breast cancer
, 4
-
(2009)
Role of SRC family kinases in acquired
resistance to EGFR therapies in cancer
, 8
-
(2016)
The afatinib resistance of
in vivo generated H1975 lung cancer cell clones is mediated by
SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
, 7
-
(2014)
Experience with afatinib in
patients with non-small cell lung cancer progressing after clinical benefit
from gefitinib and erlotinib
, 19
-
G.
Demetri,
Patricia
Russo,
I.
Macpherson,
Ding
Wang,
J.
Morgan,
T.
Evans,
Morgan
Ja,
Demetri
G,
Wang
D,
Ludwig
Center,
Dana
Farber
(2009)
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 15
-
(2011)
FGFR signaling promotes the
growth of triple-negative and basal-like breast cancer cell lines both in
vitro and in vivo
, 17
-
HER-targeted tyrosine kinase
inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive
breast cancer
-
G.
Viale,
N.
Rotmensz,
P.
Maisonneuve,
L.
Bottiglieri,
E.
Montagna,
A.
Luini,
P.
Veronesi,
M.
Intra,
R.
Torrisi,
A.
Cardillo,
E.
Campagnoli,
A.
Goldhirsch,
M.
Colleoni
(2009)
Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
Breast Cancer Research and Treatment, 116
-
(2010)
The Met oncogene and basal-like breast cancer:
another culprit to watch out for?
, 12
-
S.
Dimmeler,
K.
Breitschopf,
J.
Haendeler,
A.
Zeiher
(1999)
Dephosphorylation Targets Bcl-2 for Ubiquitin-dependent Degradation: A Link between the Apoptosome and the Proteasome Pathway
The Journal of Experimental Medicine, 189
-
(2012)
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2negative metastatic breast cancer
-
(2009)
Phase I dose-escalation and
pharmacokinetic study of dasatinib in patients with advanced solid
tumors
, 15
-
R.
Pirker,
J.
Pereira,
A.
Szczesna,
J.
Pawel,
M.
Krzakowski,
R.
Ramlau,
I.
Vynnychenko,
Keunchil
Park,
Chih-Teng
Yu,
V.
Ganul,
J.
Roh,
E.
Bajetta,
K.
O'Byrne,
F.
Marinis,
W.
Eberhardt,
T.
Goddemeier,
M.
Emig,
U.
Gatzemeier
(2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
The Lancet, 373
-
J.
Choi,
S.
Kang,
Soo
Lee,
Y.
Bae
(2014)
Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy
Tumor Biology, 35
-
(2014)
Control of apoptosis by the
BCL-2 protein family: implications for physiology and
therapy
, 15
-
R.
Finn,
J.
Dering,
C.
Ginther,
Cindy
Wilson,
Padraic
Glaspy,
N.
Tchekmedyian,
D.
Slamon
(2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro
Breast Cancer Research and Treatment, 105
-
A.
Stanley,
G.
Ashrafi,
A.
Seddon,
H.
Modjtahedi
(2017)
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Scientific Reports, 7
-
M.
Irwin,
Natacha
Bohin,
J.
Boerner
(2011)
Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells
Cancer Biology & Therapy, 12
-
S.
Maira,
F.
Stauffer,
J.
Brueggen,
P.
Furet,
C.
Schnell,
C.
Fritsch,
S.
Brachmann,
P.
Chène,
A.
Pover,
Kevin
Schoemaker,
D.
Fabbro,
Daniela
Gabriel,
M.
Simonen,
Leon
Murphy,
P.
Finan,
W.
Sellers,
C.
García-echeverría
(2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Molecular Cancer Therapeutics, 7
-
R.
Dent,
M.
Trudeau,
K.
Pritchard,
W.
Hanna,
H.
Kahn,
C.
Sawka,
L.
Lickley,
E.
Rawlinson,
P.
Sun,
S.
Narod
(2007)
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Clinical Cancer Research, 13
-
M.
Blagosklonny
(2001)
Unwinding the loop of Bcl-2 phosphorylation
Leukemia, 15
-
Y.
Bareche,
D.
Venet,
M.
Ignatiadis,
P.
Aftimos,
M.
Piccart,
F.
Rothé,
C.
Sotiriou
(2018)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Annals of Oncology, 29
-
T.
Nielsen,
Forrest
Hsu,
Kristin
Jensen,
Maggie
Cheang,
G.
Karaca,
Zhiyuan
Hu,
T.
Hernandez-Boussard,
C.
Livasy,
D.
Cowan,
L.
Dressler,
L.
Akslen,
J.
Ragaz,
A.
Gown,
C.
Gilks,
M.
Rijn,
C.
Perou
(2004)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Clinical Cancer Research, 10
-
J.
Baselga,
P.
Gómez,
R.
Greil,
S.
Braga,
M.
Climent,
Andrew
Wardley,
B.
Kaufman,
Salomon
Stemmer,
A.
Pêgo,
A.
Chan,
J.
Goeminne,
M.
Graas,
M.
Kennedy,
Eva
Gil,
A.
Schneeweiss,
A.
Zubel,
J.
Groos,
H.
Melezínková,
A.
Awada
(2013)
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 20
-
(2013)
Randomized phase II study of
the anti-epidermal growth factor receptor monoclonal antibody cetuximab with
cisplatin versus cisplatin alone in patients with metastatic triple-negative
breast cancer
, 31
-
(2013)
Inhibition of
triple-negative breast cancer models by combinations of antibodies to
EGFR
, 110
-
(2014)
cMET in triple-negative
breast cancer: is it a therapeutic target for this subset of breast cancer
patients?
, 18
-
S.
Cory,
Jerry
Adams
(2002)
The Bcl2 family: regulators of the cellular life-or-death switch
Nature Reviews Cancer, 2
-
S.
Ueng,
Shin-Cheh
Chen,
Yu-Sun
Chang,
S.
Hsueh,
Yung-Chang
Lin,
Hui-ping
Chien,
Y.
Lo,
S.
Shen,
C.
Hsueh
(2012)
Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas.
International journal of clinical and experimental pathology, 5 8
-
A.
Awada,
H.
Dumez,
A.
Hendlisz,
P.
Wolter,
T.
besse-Hammer,
M.
Uttenreuther-Fischer,
P.
Stopfer,
F.
Fleischer,
M.
Piccart,
P.
Schöffski
(2012)
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
Investigational New Drugs, 31
-
K.
Reddy
(2011)
Triple-negative breast cancers: an updated review on treatment options.
Current oncology, 18 4
-
(2007)
SRC-family kinases are
activated in non-small cell lung cancer and promote the survival of
epidermal growth factor receptor-dependent cell lines
, 170
-
Patricia
Gaule,
J.
Crown,
N.
O'Donovan,
M.
Duffy
(2014)
cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Expert Opinion on Therapeutic Targets, 18
-
(2012)
Phosphorylated mTOR
expression correlates with poor outcome in early-stage triple negative
breast carcinomas
, 5
-
R.
Irby,
T.
Yeatman
(2000)
Role of Src expression and activation in human cancer
Oncogene, 19
-
(2018)
Triple negative breast cancer: emerging
therapeutic modalities and novel combination therapies
, 62
-
K.
Stemke‐Hale,
A.
González-Angulo,
A.
Lluch,
R.
Neve,
W.
Kuo,
M.
Davies,
M.
Carey,
Zhi
Hu,
Y.
Guan,
A.
Sahin,
W.
Symmans,
L.
Pusztai,
L.
Nolden,
H.
Horlings,
K.
Berns,
M.
Hung,
M.
Vijver,
V.
Valero,
J.
Gray,
R.
Bernards,
G.
Mills,
B.
Hennessy
(2008)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Cancer research, 68 15
-
Daizong
Li,
L.
Ambrogio,
L.
Ambrogio,
T.
Shimamura,
S.
Kubo,
Masaya
Takahashi,
L.
Chirieac,
R.
Padera,
G.
Shapiro,
A.
Baum,
F.
Himmelsbach,
W.
Rettig,
M.
Meyerson,
M.
Meyerson,
F.
Solca,
H.
Greulich,
H.
Greulich,
Kwok-kin
Wong
(2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Oncogene, 27
-
(2009)
Design, structure-activity
relationships and in vivo characterization of
4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor
tyrosine kinase inhibitors
, 52
-
(2005)
Evaluating response to antineoplastic drug
combinations in tissue culture models
, 110
-
P.
Czabotar,
G.
Lessene,
A.
Strasser,
Jerry
Adams
(2013)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Nature Reviews Molecular Cell Biology, 15
-
Jie
Zhang,
Shailaja
Kalyankrishna,
M.
Wislez,
Nishan
Thilaganathan,
B.
Saigal,
Wei
Wei,
Long
Ma,
I.
Wistuba,
F.
Johnson,
J.
Kurie
(2007)
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
The American journal of pathology, 170 1
-
(2012)
Efficacy of everolimus, a
novel mTOR inhibitor, against basal-like triple-negative breast cancer
cells
, 103
-
(2013)
Phase I study of pulsatile
3-day administration of afatinib (BIBW 2992) in combination with docetaxel
in advanced solid tumors
, 31
-
H.
Nechushtan,
G.
Vainer,
Hana
Stainberg,
A.
Salmon,
T.
Hamburger,
T.
Peretz
(2014)
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Breast, 23 4
-
S.
Wind,
M.
Schmid,
Julia
Erhardt,
R.
Goeldner,
P.
Stopfer
(2013)
Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours
Clinical Pharmacokinetics, 52
-
(2001)
Unwinding the loop of Bcl-2
phosphorylation
, 15
-
(2014)
A phase 1/2 of a combination
of cetuximab and taxane for “triple negative” breast cancer
patients
, 23
-
(2018)
Targeting SRC kinase blocks
development of afatinib resistance in HER2-positive breast
cancer
, 78
-
T.
Mahgoub,
A.
Eustace,
D.
Collins,
N.
Walsh,
N.
O'Donovan,
J.
Crown
(2015)
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
International Journal of Oncology, 47
-
(2016)
Refinement of
triple-negative breast cancer molecular subtypes: implications for
neoadjuvant chemotherapy selection
, 11
-
(2011)
SRCfamily kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells
-
B.
Corkery,
J.
Crown,
M.
Clynes,
N.
O'Donovan
(2009)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 5
-
(2015)
Kinase inhibitor screening
identifies CDK4 as a potential therapeutic target for
melanoma
, 47
-
(2008)
An integrative genomic and
proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast
cancer
, 68
-
(2011)
Identification of human
triple-negative breast cancer subtypes and preclinical models for selection
of targeted therapies
, 121
-
K.
Bouchalová,
M.
Svoboda,
G.
Kharaishvili,
J.
Vrbková,
J.
Bouchal,
R.
Trojanec,
V.
Koudelakova,
L.
Radová,
K.
Cwiertka,
M.
Hajdůch,
Z.
Kolár̂
(2015)
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy
Tumor Biology, 36
-
(2005)
In vitro activity of Bcr-Abl
inhibitors AMN107 and BMS-354825 against clinically relevant
imatinib-resistant Abl kinase domain mutants
, 65
-
(2007)
The triple negative paradox:
primary tumor chemosensitivity of breast cancer subtypes
, 13
-
(2011)
Dual kinase inhibition of EGFR and HER2
overcomes resistance to cetuximab in a novel in vivo model of acquired
cetuximab resistance
, 17
-
(2012)
A phase II trial to assess
efficacy and safety of afatinib in extensively pretreated patients with
HER2-negative metastatic breast cancer
, 134
-
C.
Reynolds,
B.
Maurer
(2005)
Evaluating response to antineoplastic drug combinations in tissue culture models.
Methods in molecular medicine, 110
-
(2012)
Potential of afatinib in the
treatment of patients with HER2-positive breast cancer
, 4
-
Alice
Lee,
M.
Djamgoz
(2018)
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Cancer treatment reviews, 62
-
D.
Ferraro,
N.
Gaborit,
R.
Maron,
H.
Cohen-Dvashi,
Z.
Porat,
F.
Pareja,
S.
Lavi,
Moshit
Lindzen,
N.
Ben-Chetrit,
M.
Sela,
Y.
Yarden
(2013)
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
Proceedings of the National Academy of Sciences, 110
-
C.
Criscitiello,
H.
Azim,
P.
Schouten,
S.
Linn,
C.
Sotiriou
(2012)
Understanding the biology of triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 6
-
P.
Renhowe,
S.
Pecchi,
C.
Shafer,
Timothy
Machajewski,
Elisa
Jazan,
Clarke
Taylor,
William
Antonios-Mccrea,
Christopher
Mcbride,
Kelly
Frazier,
M.
Wiesmann,
Gena
Lapointe,
P.
Feucht,
R.
Warne,
C.
Heise,
D.
Menezes,
K.
Aardalen,
Helen
Ye,
M.
He,
V.
Le,
J.
Vora,
J.
Jansen,
M.
Wernette-Hammond,
A.
Harris
(2009)
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry, 52 2
-
(2007)
The rapamycin-binding domain of the protein
kinase mammalian target of rapamycin is a destabilizing
domain
, 282
-
D.
Tryfonopoulos,
S.
Walsh,
D.
Collins,
L.
Flanagan,
C.
Quinn,
B.
Corkery,
E.
McDermott,
D.
Evoy,
A.
Pierce,
N.
O'Donovan,
J.
Crown,
M.
Duffy
(2011)
Src: a potential target for the treatment of triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 10
-
(2017)
Olaparib for metastatic
breast cancer in patients with a germline BRCA mutation
, 377
-
HERtargeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Invest New Drugs. Epub ahead of print
-
(2000)
Role of Src expression and activation in human
cancer
, 19
-
B.
Lehmann,
Joshua
Bauer,
X.
Chen,
M.
Sanders,
A.
Chakravarthy,
Y.
Shyr,
J.
Pietenpol
(2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
The Journal of clinical investigation, 121 7
-
(2018)
Targeting SRC kinase blocks development of afatinib resistance in HER2-positive breast cancer
-
M.
Robson,
S.
Im,
E.
Senkus,
Bing-he
Xu,
S.
Domchek,
N.
Masuda,
S.
Delaloge,
Wei
Li,
N.
Tung,
A.
Armstrong,
Wenting
Wu,
C.
Goessl,
S.
Runswick,
P.
Conte
(2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
The New England Journal of Medicine, 377
-
(2018)
Unravelling triple-negative
breast cancer molecular heterogeneity using an integrative multiomic
analysis
, 29
-
(2013)
Pharmacokinetics of
afatinib, a selective irreversible ErbB family blocker, in patients with
advanced solid tumours
, 52
-
C.
Denkert,
C.
Liedtke,
A.
Tutt,
G.
Minckwitz
(2017)
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
The Lancet, 389
-
S.
Hurvitz,
Rebecca
Shatsky,
N.
Harbeck
(2014)
Afatinib in the treatment of breast cancer
Expert Opinion on Investigational Drugs, 23
-
J.
O’Shea,
M.
Cremona,
C.
Morgan,
Małgorzata
Milewska,
F.
Holmes,
V.
Espina,
L.
Liotta,
J.
O’Shaughnessy,
S.
Toomey,
S.
Madden,
A.
Carr,
N.
Elster,
B.
Hennessy,
A.
Eustace
(2017)
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
Oncotarget, 8
-
T.
Abdel-Fatah,
Christina
Perry,
P.
Dickinson,
G.
Ball,
P.
Moseley,
S.
Madhusudan,
I.
Ellis,
S.
Chan
(2013)
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 11
-
(2007)
Dasatinib, an orally active
small molecule inhibitor of both the src and abl kinases, selectively
inhibits growth of basal-type/“triple-negative” breast cancer cell lines
growing in vitro
, 105
-
(2015)
BCL2 is an independent
predictor of outcome in basal-like triple-negative breast cancers treated
with adjuvant anthracycline-based chemotherapy
, 36
-
M.
Schuler,
A.
Awada,
P.
Harter,
J.
Canon,
K.
Possinger,
Marcus
Schmidt,
J.
Grève,
P.
Neven,
L.
Dirix,
W.
Jonat,
M.
Beckmann,
J.
Schütte,
P.
Fasching,
N.
Gottschalk,
T.
besse-Hammer,
F.
Fleischer,
S.
Wind,
M.
Uttenreuther-Fischer,
M.
Piccart,
N.
Harbeck
(2012)
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Breast Cancer Research and Treatment, 134
-
(2005)
A multicentre phase II study
on gefitinib in taxane- and anthracycline-pretreated metastatic breast
cancer
, 89
-
(2014)
Prognostic significance of
Bcl-2 expression in non-basal triple-negative breast cancer patients treated
with anthracycline-based chemotherapy
, 35
-
L.
Carey,
E.
Dees,
L.
Sawyer,
Lisa
Gatti,
D.
Moore,
F.
Collichio,
D.
Ollila,
Carolyn
Sartor,
M.
Graham,
C.
Perou
(2007)
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Clinical Cancer Research, 13
-
Takeshi
Yoshida,
Guolin
Zhang,
Matthew
Smith,
Alexis
Lopez,
Y.
Bai,
Jiannong
Li,
B.
Fang,
J.
Koomen,
B.
Rawal,
K.
Fisher,
Ann
Chen,
M.
Kitano,
Yume
Morita,
H.
Yamaguchi,
K.
Shibata,
T.
Okabe,
I.
Okamoto,
K.
Nakagawa,
E.
Haura
(2014)
Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Clinical Cancer Research, 20
-
M.
Yunokawa,
F.
Koizumi,
Yuka
Kitamura,
Y.
Katanasaka,
Naoko
Okamoto,
M.
Kodaira,
K.
Yonemori,
C.
Shimizu,
M.
Ando,
K.
Masutomi,
Teruhiko
Yoshida,
Y.
Fujiwara,
K.
Tamura
(2012)
Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cells
Cancer Science, 103
-
(2014)
Afatinib in the treatment of breast
cancer
, 23
-
(2010)
A technical assessment of
the utility of reverse phase protein arrays for the study of the functional
proteome in non-microdissected human breast cancers
, 6
-
(1999)
Dephosphorylation targets
Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and
the proteasome pathway
, 189
-
(2008)
BIBW2992, an irreversible
EGFR/HER2 inhibitor highly effective in preclinical lung cancer
models
, 27
-
(2008)
Identification and
characterization of NVP-BEZ235, a new orally available dual
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with
potent in vivo antitumor activity
, 7
-
(2014)
Tyrosine phosphoproteomics
identifies both codrivers and cotargeting strategies for T790M-related
EGFR-TKI resistance in non-small cell lung cancer
, 20
-
(2007)
Triple-negative breast
cancer: clinical features and patterns of recurrence
, 13
-
(2017)
Synergistic effects of
various Her inhibitors in combination with IGF-1R, C-MET and SRC targeting
agents in breast cancer cell lines
, 7
-
J.
Boerner
(2009)
Role of Src family kinases in acquired resistance to EGFR therapies in cancer
Cancer Biology & Therapy, 8
-
(2012)
Target binding properties
and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family
blocker
, 343
-
Fawn
Qian,
S.
Engst,
K.
Yamaguchi,
P.
Yu,
K.
Won,
Lillian
Mock,
Tracy
Lou,
Jenny
Tan,
Connie
Li,
D.
Tam,
J.
Lougheed,
F.
Yakes,
F.
Bentzien,
W.
Xu,
T.
Zaks,
R.
Wooster,
J.
Greshock,
A.
Joly
(2009)
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Cancer research, 69 20
-
(2011)
Triple-negative breast cancers: an updated
review on treatment options
, 18
-
(2013)
It takes two to tango: dual inhibition of PI3K
and MAPK in rhabdomyosarcoma
, 19
-
Alexandra
Canonici,
L.
Ivers,
N.
Conlon,
Kasper
Pedersen,
N.
Gaynor,
B.
Browne,
Neil
O’Brien,
G.
Gullo,
D.
Collins,
N.
O'Donovan,
J.
Crown
(2018)
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
Investigational New Drugs, 37
-
Lisa
Volk-Draper,
S.
Rajput,
Kelly
Hall,
A.
Wilber,
S.
Ran
(2012)
Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.
Neoplasia, 14 10
-
V.
Heinemann,
S.
Stintzing,
T.
Kirchner,
S.
Boeck,
A.
Jung
(2009)
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Cancer treatment reviews, 35 3
-
(2009)
Clinical relevance of EGFR-
and KRAS-status in colorectal cancer patients treated with monoclonal
antibodies directed against the EGFR
, 35
-
B.
Lehmann,
B.
Jovanovic,
Xi
Chen,
M.
Estrada,
Kimberly
Johnson,
Y.
Shyr,
H.
Moses,
M.
Sanders,
J.
Pietenpol
(2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
PLoS ONE, 11
-
S.
Gastaldi,
P.
Comoglio,
L.
Trusolino
(2010)
The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Breast Cancer Research : BCR, 12
-
(2009)
Epidermal growth factor
receptor as a potential therapeutic target in triple-negative breast
cancer
, 20
-
(2009)
Inhibition of tumor cell
growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel
inhibitor of HGF and VEGF receptor tyrosine kinases
, 69
-
E.
Geuna,
F.
Montemurro,
M.
Aglietta,
G.
Valabrega
(2012)
Potential of afatinib in the treatment of patients with HER2-positive breast cancer.
Breast cancer, 4
-
T.
O'hare,
D.
Walters,
E.
Stoffregen,
Taiping
Jia,
P.
Manley,
J.
Mestan,
S.
Cowan-Jacob,
F.
Lee,
M.
Heinrich,
M.
Deininger,
B.
Druker
(2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Cancer research, 65 11
-
B.
Hennessy,
Yiling
Lu,
A.
González-Angulo,
M.
Carey,
S.
Myhre,
Z.
Ju,
M.
Davies,
Wenbin
Liu,
K.
Coombes,
F.
Meric-Bernstam,
I.
Bedrosian,
Mollianne
McGahren,
R.
Agarwal,
Fan
Zhang,
J.
Overgaard,
J.
Alsner,
R.
Neve,
W.
Kuo,
J.
Gray,
A.
Børresen-Dale,
G.
Mills
(2010)
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
Clinical Proteomics, 6
-
(2018)
HERtargeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
-
(2008)
inhibitor highly effective in preclinical lung cancer models
-
(2012)
Novel model for basaloid
triple-negative breast cancer: behaviour in vivo and response to
therapy
, 14
-
M.
Schuler,
J.
Fischer,
C.
Grohé,
S.
Gütz,
Michael
Thomas,
M.
Kimmich,
C.
Schneider,
E.
Laack,
A.
Märten
(2014)
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
The oncologist, 19 10
-
F.
Solca,
G.
Dahl,
A.
Zoephel,
G.
Bader,
M.
Sanderson,
C.
Klein,
O.
Kraemer,
F.
Himmelsbach,
E.
Haaksma,
G.
Adolf
(2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Journal of Pharmacology and Experimental Therapeutics, 343
-
(2009)
Cetuximab plus chemotherapy
in patients with advanced non-small-cell lung cancer (FLEX): an open-label
randomised phase III trial
, 373
-
Sarah
Edwards,
T.
Wandless
(2007)
The Rapamycin-binding Domain of the Protein Kinase Mammalian Target of Rapamycin Is a Destabilizing Domain*
Journal of Biological Chemistry, 282
-
(2017)
A preclinical evaluation of
the MEK inhibitor refametinib in HER2-positive breast cancer cell lines
including those with acquired resistance to trastuzumab or
lapatinib
, 8
-
Kelly
Quesnelle,
J.
Grandis
(2011)
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Clinical Cancer Research, 17